GSK Buys Cancer Drug Company Nuvalent for $10.6 Billion

Pharmaceutical giant GSK announced plans to acquire Nuvalent, a U.S. cancer specialist, for $10.6 billion—its largest deal in 13 years. The purchase reflects GSK's shift toward specialty drugs after spinning off its consumer health division in 2022. Nuvalent develops treatments for lung cancer mutations that GSK currently doesn't address, filling a gap in its cancer portfolio.